Since its discovery as a cancer-testis antigen, the immunotherapeutic targeting of SSX has raised great interest as an anti-cancer strategy due to its immunogenicity [2], [3], restricted tumor expression, and correlation between SSX expression and disease progression [8], [17], [18]. This evidence concerns the gene SSX2 and neoplasm.